Brucine as a Natural Modulator of Cancer Signaling: Cellular Mechanisms, Therapeutic Potential, and Translational...

Area of Science:

• Pharmacology
• Natural Products Chemistry
• Oncology

Background:

• Brucine (BRU) is an indole alkaloid from Strychnos nux-vomica with emerging anticancer properties.
• Preclinical studies indicate BRU's efficacy against diverse cancer types, including cervical, breast, liver, skin, colon, and prostate cancers.

Purpose of the Study:

• To review the phytochemical characteristics, chemical modifications, and anticancer mechanisms of Brucine.
• To evaluate Brucine's bioavailability, pharmacokinetics, clinical findings, toxicity, and safety profile.
• To explore Brucine's potential as a natural alternative to conventional chemotherapy.

Main Methods:

• Literature review of preclinical and clinical studies on Brucine's anticancer activity.
• Analysis of phytochemical properties, chemical modifications, and pharmacokinetic data.
• Assessment of toxicity profiles and safety evaluations.

Main Results:

• Brucine and its derivatives demonstrate significant tumor inhibitory effects across multiple cancer models.
• Brucine exhibits broad-spectrum efficacy, offering a potential alternative to existing chemotherapeutic agents.
• Therapeutic application is currently limited by a narrow safety margin.

Conclusions:

• Brucine presents a promising natural compound for anticancer therapy due to its broad-spectrum activity.
• Development of optimized semi-synthetic derivatives and advanced drug delivery systems is crucial.
• Future research should focus on enhancing pharmacological performance and minimizing toxicity for clinical viability.